PDE5 inhibitors (Mitsubishi Tanabe Pharma/Nagoya University)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamePDE5 inhibitors (Mitsubishi Tanabe Pharma/Nagoya University)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 5A inhibitors
TargetsPhosphodiesterase 5A
Therapy Area/IndicationsErectile DysfunctionPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNagoya UniversityMitsubishi Tanabe Pharma Corp
Active IndicationsN/A
Inactive IndicationsErectile DysfunctionPulmonary Arterial Hypertension

Other Information

ATC CodeN/A
Related LinksN/A